Back to search

University of Thessaly (UTH)

Evaluation of the humoral immune response against survivin in patients with lung cancer

Abstract

dc:description

Autoantibodies have been shown to be present in the circulation of people with various forms of solid tumours before cancer-associated antigens can be detected. Unlike circulating proteins that are shed by bulky tumors, autoantibodies are detectable even when antigen expression is minimal and they can be measured up to 5 years prior to disease detection. They are usually directed against oncoproteins, aberrantly expressed tumour suppression genes, proliferation-associated antigens as well as nuclear antigens. Existing evidence regarding spontaneous anti-survivin humoral responses in lung cancer is inconclusive. Moreover, despite that cancer cell death elicited by radiotherapy and some chemotherapeutic agents seems to be immunogenic, information about the possible effect of treatment on these responses, is lacking. Serum samples from 33 small cell lung cancer (SCLC) and 117 non-small cell lung cancer (NSCLC) patients upon diagnosis, and from 100 controls, were tested by ELISA for anti-survivin antibodies. Cutoff was set to the mean+2SD of controls. 7.7% of NSCLC, none of the SCLC patients and 2% of the controls appeared with elevated antibody levels (OR 3.6, 95% CI 0.7-17.3 for NSCLC, OR 0.6, 95% CI 0.03-12.6 for SCLC). Measurement of antibodies in 76 NCSLC patients post therapies and during their follow-up, revealed 12 NSCLC patients that increased their antibody levels up to 2-38 times, and 7 others that decreased them by 2-8 times. No significant correlation was uncovered between either the antibody levels upon diagnosis or their changes post therapies and during follow-up, and any clinicopathological parameter, their response to treatment and survival. We conclude that survivin does not induce considerable humoral responses in lung cancer. Potentially, however, strong anti-survivin antibody responses can be elicited during the follow-up of the patients, whose clinical significance remains to be elucidated. These findings, together with our previous data concerning survivin expression and the related cytolytic T cell responses in lung cancer, signify a high tolerogenic potential of this tumor-associated antigen.

Degree

thesis:*
Grantor dc:publisher
University of Thessaly (UTH)
Year dc:date
2009

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Khalil, Sanaa

Subjects

dc:subject × 10

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/18170

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Khalil, Sanaa. Evaluation of the humoral immune response against survivin in patients with lung cancer. University of Thessaly (UTH), 2009. http://hdl.handle.net/10442/hedi/18170